Biote said Chief Executive Officer Terry Weber is expected to retire effective Feb. 1, and would be succeeded by Bret Christensen. The hormone- and therapeutic-health and wellness company said Weber ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...
The Rotterdam Film Festival’s IFFR Pro industry program kicks off Friday under the fresh direction of new head Martens ...
We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...
New WWF-led research reveals that the vital benefits wildlife provides to people's everyday lives are vastly underrepresented ...
Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that ...
In today’s fast-paced world, where the stresses of daily life often take a toll on our health, it is essential to find ...
Mysterious Blobs Found inside Cells Are Rewriting the Story of How Life Works Tiny specks called biomolecular condensates are ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback